Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 8:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 1,045 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Congenital Anemias Clear all
Completed No phase listed Observational

Identifying Barriers and Strategies to Support Self-efficacy for Medication Adherence With Text Messaging

NCT02785848
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Interviews and Surveys
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
12 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 18, 2026, 8:55 AM EDT
Completed No phase listed Observational Results available

Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence

NCT00300235
View directory record Official record
Conditions
Priapism, Anemia, Sickle Cell
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
5 Years and older · Male only
Enrollment
1,464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
27
States / cities
Mobile, Alabama • Davis, California • Oakland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 18, 2026, 8:55 AM EDT
Completed No phase listed Observational

Diabetic Retinopathy and Sickle Trait

NCT00720317
View directory record Official record
Conditions
Diabetic Retinopathy, Sickle Cell Trait
Interventions
Not listed
Lead sponsor
Medical University of South Carolina
Other
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 16, 2010 · Synced Oct 18, 2026, 8:55 AM EDT
Completed Not applicable Interventional

Preliminary Feasibility and Efficacy of Behavioral Intervention to Reduce Pain-Related Disability in Pediatric SCD

NCT04388241
View directory record Official record
Conditions
Sickle Cell Disease, Pain
Interventions
The Balance Program
Behavioral
Lead sponsor
Children's National Research Institute
Other
Eligibility
8 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Oct 18, 2026, 8:55 AM EDT
Completed Phase 2 Interventional Results available

Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment

NCT00447694
View directory record Official record
Conditions
Beta-thalassemia, Iron Overload
Interventions
Deferasirox
Drug
Lead sponsor
Novartis
Industry
Eligibility
10 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Los Angeles, California • Oakland, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 18, 2026, 8:55 AM EDT
Terminated Phase 2 Interventional

Inhaled Nitric Oxide for Pediatric Painful Sickle Crisis

NCT00142051
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
nitric oxide, oxygen
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
9 Years to 22 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 18, 2026, 8:55 AM EDT
Terminated Phase 3 Interventional Results available

Clinical Importance of Treating Iron Overload in Sickle Cell Disease

NCT00981370
View directory record Official record
Conditions
Anemia, Sickle Cell, Transfusion Hemosiderosis
Interventions
deferasirox
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
14 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 18, 2026, 8:55 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)

NCT05444894
View directory record Official record
Conditions
Transfusion Dependent Beta Thalassemia, Hemoglobinopathies, Thalassemia Major, Thalassemia Intermedia
Interventions
EDIT-301
Genetic
Lead sponsor
Editas Medicine, Inc.
Industry
Eligibility
18 Years to 35 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Oakland, California • Minneapolis, Minnesota • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 18, 2026, 8:55 AM EDT
Completed Phase 4 Interventional

Voxelotor Sickle Cell Exercise Study

NCT04581356
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
Voxelotor
Drug
Lead sponsor
Elizabeth Yang, MD, PhD
Other
Eligibility
12 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 18, 2026, 8:55 AM EDT
Completed Phase 1 Interventional Results available

A Study to Evaluate GBT021601-012 Single Dose and Multiple Dose in Participants With Sickle Cell Disease (SCD)

NCT04983264
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
GBT021601
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Miami, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Oct 18, 2026, 8:55 AM EDT
Completed Phase 2 Interventional Results available

Pain Management in Children and Young Adults With Sickle Cell Disease

NCT01954927
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 20 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Oct 18, 2026, 8:55 AM EDT
Completed Phase 1 Interventional

A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease

NCT01597401
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Aes-103, Placebo
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 18, 2026, 8:55 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function

NCT06145282
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Briquilimab, Filgrastim, Abatacept, Sirolimus, Cyclophosphamide
Biological · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
4 Years to 100 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 18, 2026, 8:55 AM EDT
Completed Not applicable Interventional

MBSR for Pain Catastrophizing in SCD

NCT02394587
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Mindfulness-based Stress Reduction
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 29, 2017 · Synced Oct 18, 2026, 8:55 AM EDT
Withdrawn Phase 2 Interventional

Comparison of Patient Controlled Analgesia (PCA) Versus Bolus Narcotic Therapy for the Treatment of Vaso-Occlusive Crisis (VOC)

NCT00711698
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis
Interventions
Patient controlled analgesia, nurse-administered intermittent IV bolus opioid therapy (NAIBOD)
Procedure · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 18, 2026, 8:55 AM EDT
Completed Not applicable Interventional

Applying Directly Observed Therapy to Hydroxyurea to Realize Effectiveness

NCT06264700
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Video Directly Observed Therapy (VDOT), Health Reminder Tip Alerts
Behavioral
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
11 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Chicago, Illinois • Columbus, Ohio • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 18, 2026, 8:55 AM EDT
Active, not recruiting Not applicable Interventional

Sickle Cell Children's Exercise Study (SuCCESs)

NCT06074198
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
SuCCESs
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
6 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 18, 2026, 8:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of Nitric Oxide and Nitroglycerin in Patients With Sickle Cell Anemia

NCT00001716
View directory record Official record
Conditions
Chest Pain, Sickle Cell Anemia
Interventions
Nitric Oxide, Nitroglycerin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 18, 2026, 8:55 AM EDT
Completed Phase 1Phase 2 Interventional

Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission

NCT00305708
View directory record Official record
Conditions
Congenital Amegakaryocytic Thrombocytopenia, Diamond-blackfan Anemia, Fanconi Anemia, Leukemia, Severe Congenital Neutropenia, Thrombocytopenia
Interventions
anti-thymocyte globulin, busulfan, fludarabine phosphate, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, umbilical cord blood transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2012 · Synced Oct 18, 2026, 8:55 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)

NCT04853576
View directory record Official record
Conditions
Sickle Cell Disease, Hemoglobinopathies
Interventions
EDIT-301
Genetic
Lead sponsor
Editas Medicine, Inc.
Industry
Eligibility
12 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
21
States / cities
Oakland, California • Aurora, Colorado • New Haven, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 18, 2026, 8:55 AM EDT
Terminated Phase 2 Interventional

Hospital-Based Program for Treatment of Severe Cardiopulmonary Disease With Inhaled Nitric Oxide

NCT00041574
View directory record Official record
Conditions
Pulmonary Hypertension, Lung Disease, Sickle Cell Disease, Cardiac Transplant, Lung Transplant
Interventions
Inhaled Nitric Oxide
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
5 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
3
States / cities
Denver, Colorado • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 18, 2026, 8:55 AM EDT
Completed Phase 2 Interventional Results available

A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia

NCT03342404
View directory record Official record
Conditions
Thalassemia
Interventions
Luspatercept, Placebo, Best Supportive Care (BSC)
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Los Angeles, California • Oakland, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 18, 2026, 8:55 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Lidocaine Intravenous in the Emergency Department For Sickle Cell Crisis

NCT04614610
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Crisis, Pain, Acute
Interventions
Lidocaine Iv, Placebo
Drug
Lead sponsor
Community Medical Center, Toms River, NJ
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Long Branch, New Jersey • New Brunswick, New Jersey • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Oct 18, 2026, 8:55 AM EDT
Enrolling by invitation No phase listed Observational

ASH Research Collaborative Data Hub

NCT05775224
View directory record Official record
Conditions
Sickle Cell Disease, Multiple Myeloma
Interventions
Not listed
Lead sponsor
ASH Research Collaborative
Other
Eligibility
Not listed
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2099
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Oct 18, 2026, 8:55 AM EDT